The corporate venture arm of an Australian-based company specializing in infection prevention technology, primarily in the hospital setting is interested in strategic investments and acquisitions, spanning benchtop proof of concept to businesses selling products into the market. Within the area of infection prevention and control, the firm will consider digital health, diagnostics and medical device technologies that relate to infection, but will not invest in pharmaceutical therapeutics. Investments can range from less than $1M, up to enterprise scale acquisitions. The firm will invest globally.
The firm has a focus on digital health, diagnostics and medical device technologies that address infection prevention and control, with a focus on healthcare-acquired infection.
The firm will only make strategic investments that align with the corporate’s core business. The firm is an active investor, and will typically take a board seat after investing.
If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.
Leave a Reply